Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 26.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensa |
Stammdaten
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Unternehmen & Branche
| Name | REVVITY, INC. |
|---|---|
| Ticker | RVTY |
| CIK | 0000031791 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Diagnostics & Research |
| SIC | 3826 · Laboratory Analytical Instruments |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 9,13 Mrd. USD |
| Beta | 1,13 |
| Dividendenrendite | 0,28 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-28 | 10-K | 2,856,051,000 | 241,201,000 | 2.07 | 12,168,411,000 | 7,250,360,000 |
| 2025-09-28 | 10-Q | 698,949,000 | 46,652,000 | 0.40 | 12,138,952,000 | 7,375,896,000 |
| 2025-06-29 | 10-Q | 720,284,000 | 53,948,000 | 0.46 | 12,362,789,000 | 7,556,168,000 |
| 2025-03-30 | 10-Q | 664,762,000 | 42,237,000 | 0.35 | 12,360,724,000 | 7,637,130,000 |
| 2024-12-29 | 10-K | 2,755,026,000 | 270,385,000 | 2.20 | 12,392,478,000 | 7,666,874,000 |
| 2024-09-29 | 10-Q | 684,049,000 | 94,367,000 | 0.77 | 12,769,737,000 | 7,921,701,000 |
| 2024-06-30 | 10-Q | 691,685,000 | 55,360,000 | 0.45 | 13,424,849,000 | 7,870,314,000 |
| 2024-03-31 | 10-Q | 649,920,000 | 26,013,000 | 0.21 | 13,432,705,000 | 7,846,496,000 |
| 2023-12-31 | 10-K | 2,750,571,000 | 693,094,000 | 5.55 | 13,564,665,000 | 7,872,739,000 |
| 2023-10-01 | 10-Q | 670,739,000 | 9,497,000 | 0.08 | 13,421,548,000 | 7,694,281,000 |
| 2023-07-02 | 10-Q | 709,066,000 | 35,559,000 | 0.28 | 14,218,549,000 | 7,869,958,000 |
| 2023-04-02 | 10-Q | 674,865,000 | 569,475,000 | 4.50 | 14,638,155,000 | 8,033,810,000 |
| 2023-01-01 | 10-K | 3,311,822,000 | 127,658,000 | 1.01 | 14,129,855,000 | 7,382,876,000 |
| 2022-10-02 | 10-K | 711,803,000 | 85,347,000 | 0.67 | ||
| 2022-10-02 | 10-Q | 711,803,000 | 85,347,000 | 0.67 | 13,823,764,000 | 7,065,200,000 |
| 2022-07-03 | 10-K | 895,642,000 | 179,212,000 | 1.42 | ||
| 2022-07-03 | 10-Q | 895,642,000 | 179,212,000 | 1.42 | 14,189,707,000 | 7,167,155,000 |
| 2022-04-03 | 10-K | 963,163,000 | 176,962,000 | 1.39 | ||
| 2022-04-03 | 10-Q | 963,163,000 | 176,962,000 | 1.40 | 14,848,467,000 | 7,186,342,000 |
| 2022-01-02 | 10-K | 1,027,910,000 | 190,184,000 | 1.50 | 15,000,554,000 | 7,141,245,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-20 | Gonzales Anita | Officer, Vice President and CAO | Open Market Sale | -80 | 92.80 | -7,424.00 | -2,3% | |
| 2026-02-24 | Victor Miriame | Officer, Please See Remarks | Open Market Sale | -1,862 | 97.13 | -180,856.06 | -56,8% | |
| 2026-02-23 | McMurry-Heath Michelle | Director | Open Market Sale | -600 | 97.26 | -58,356.00 | -18,3% | |
| 2026-02-05 | Goldberg Joel S | Officer, Please See Remarks | Open Market Sale | -3,544 | 100.50 | -356,172.00 | -111,8% | |
| 2026-02-05 | Goldberg Joel S | Officer, Please See Remarks | Open Market Sale | -6,424 | 99.47 | -638,995.28 | -200,5% | |
| 2026-02-05 | Singh Prahlad R. | Director, Officer, Please See Remarks | Open Market Sale | -1,307 | 99.02 | -129,419.14 | -40,6% | |
| 2026-02-05 | Singh Prahlad R. | Director, Officer, Please See Remarks | Open Market Sale | -3,079 | 101.45 | -312,364.55 | -98,0% | |
| 2026-02-05 | Singh Prahlad R. | Director, Officer, Please See Remarks | Open Market Sale | -7,885 | 100.63 | -793,467.55 | -249,0% | |
| 2026-02-05 | Singh Prahlad R. | Director, Officer, Please See Remarks | Open Market Sale | -12,186 | 99.55 | -1,213,116.30 | -380,7% | |
| 2026-02-05 | Singh Prahlad R. | Director, Officer, Please See Remarks | Open Market Sale | -1,068 | 102.52 | -109,491.36 | -34,4% | |
| 2026-02-05 | Goldberg Joel S | Officer, Please See Remarks | Open Market Sale | -532 | 102.52 | -54,540.64 | -17,1% | |
| 2026-02-05 | Goldberg Joel S | Officer, Please See Remarks | Open Market Sale | -2,217 | 101.33 | -224,648.61 | -70,5% | |
| 2026-02-02 | Vohra Tajinder S | Officer, Please See Remarks | Open Market Sale | -5,756 | 104.50 | -601,502.00 | -188,7% | |
| 2025-08-27 | MICHAS ALEXIS P | Director | Open Market Sale | -500 | 89.01 | -44,505.00 | -14,0% | |
| 2025-05-29 | McMurry-Heath Michelle | Director | Open Market Sale | -600 | 92.17 | -55,299.00 | -17,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.